PrivacyPoint
Every clinical trial runs on sensitive health data. And if you're sponsoring trials in the European Union, the United Kingdom, or anywhere across the European Economic Area, the General Data Protection Regulation touches nearly every decision you make — from how you structure site agreements to what participants are told on the first day they sign up.
For privacy and legal teams, three documents tend to concentrate most of the risk: the Clinical Trial Agreement (CTA) that governs your relationship with each trial site, the Data Processing Agreements (DPAs) you execute with your vendor network, and the Informed Consent Form (ICF) that participants receive before a single data point is collected. Get these right, and you have a compliance foundation that holds up under regulatory scrutiny. Get them wrong, and you're managing fines, ethics objections, and study delays at the worst possible moment.
This is a practical look at how to approach all three — and how to build them into a clinical trial program that doesn't treat privacy as an afterthought.
The Contract That Sets the Tone: Clinical Trial Agreements
A CTA is easy to think of as a formality — a document you circulate before the real work begins. But regulators have become much more interested in what these contracts actually say about data protection, and the consequences of vague or missing clauses can be significant.
The International Council for Harmonisation's Good Clinical Practice standard requires sponsors to have a CTA in place with every trial site. What it doesn't do is tell you how to handle the GDPR dimensions, and that's where things get complicated.
The first question to answer is: what role does each party actually play? For sponsors, the answer is almost always controller — you're the one setting the purposes and the means of processing. But for sites, it's genuinely varied. In France and the UK, sites often operate as processors under sponsor instruction. In Italy and Spain, they more commonly function as independent controllers. In some arrangements, joint controllership is the most accurate characterization. Getting this wrong doesn't just create legal exposure; it creates confusion about who handles data subject requests, who notifies regulators after a breach, and who owns transparency obligations to participants.
When a site acts as an independent or joint controller, the CTA needs to function as a Data Sharing Agreement — one that clearly defines who does what when something goes wrong, and who is responsible for keeping participants informed. When the site is processing data on sponsor instructions, you need a robust Article 28-compliant DPA either embedded in the CTA or attached to it. That agreement needs to address the fundamentals: processing only on documented sponsor instructions, appropriate security measures, confidentiality obligations for site staff, meaningful support for data subject rights and breach notification, and clear terms around what happens to personal data when the trial concludes.
One detail worth getting right early: who actually signs the CTA? If a CRO signs on behalf of the sponsor, or if the Principal Investigator signs in a personal rather than institutional capacity, the controller and processor designations in the agreement may not reflect reality. These are the kinds of gaps that regulators find, and that opposing counsel notices in litigation.
Moving Data Across Borders: SCCs, the IDTA, and Transfer Assessments
Most global trials don't keep data within a single jurisdiction. Coded participant data moves to central labs in the United States. Imaging goes to cloud platforms hosted in Asia. Safety databases are managed by vendors in countries that have no adequacy decision with the EU. All of that is normal — and all of it needs a legal basis to be lawful under GDPR.
It's worth pausing on what "coded data" actually means here, because the term is often misunderstood in ways that create real compliance risk. In a clinical trial context, coded data refers to information where direct identifiers — a participant's name, contact details, date of birth — have been replaced with a unique subject identification code. The key that links that code back to the individual sits separately with the investigator or another trusted party. This is pseudonymisation, not anonymisation, and the distinction matters enormously. For the sponsor and any recipient who could reasonably obtain that key, coded data is still personal data, still subject to GDPR, and still subject to transfer restrictions. Treating a coded dataset as if it were anonymous because the name isn't visible is one of the more common compliance errors in clinical research.
For EU sponsors, the 2021 Standard Contractual Clauses remain the primary tool for transfers to non-adequate countries. Module 2 covers controller-to-processor flows, which applies to most vendor relationships. Module 1 or Module 4 handles controller-to-controller arrangements, such as transfers to a US research collaborator who is independently determining processing purposes. UK sponsors have the International Data Transfer Agreement as their primary mechanism, or they can supplement the EU SCCs with a UK Addendum. Where US vendors are certified under the EU-US Data Privacy Framework, the framework can simplify things — though many sponsors still layer SCCs on top, particularly when sub-processors in other third countries are involved.
What's increasingly non-negotiable is the Transfer Impact Assessment. EU law requires sponsors to evaluate the legal landscape of each destination country — specifically, whether local surveillance or enforcement practices undermine the protections your contracts are supposed to provide. That assessment should connect directly to the annexes of your SCCs, not exist as a standalone document that no one consults again after signing. In the UK, the equivalent is called a Transfer Risk Assessment, and the logic is the same.
From a CTA perspective, all of this means identifying the transfer mechanism for each data flow before the agreement is signed, including detailed annexes that describe what categories of data are moving, to whom, and where. Vague provisions like "data may be transferred internationally in accordance with applicable law" satisfy no one — not the EDPB, not national supervisory authorities, and not ethics committees doing their job carefully.
Managing Vendors: The Clinical Supply Chain and Article 28
Sponsors don't run clinical trials alone. A typical trial involves a CRO managing operations, an Electronic Data Capture platform collecting participant data, an Electronic Trial Master File system housing documentation, a CTMS tracking sites and enrollment, a central lab processing samples, and often a safety database managed by an external provider. Some trials add patient support programs, home visit services, or remote monitoring platforms on top of all that.
Most of these entities are processors under GDPR, and Article 28 requires a DPA with each one. But before you can write good DPAs, you need to know which vendors actually qualify as processors versus independent controllers, and which might sit outside GDPR's reach entirely. A logistics company moving coded, de-identified samples without access to the identification key may not be processing personal data at all. A research collaborator who is drawing its own scientific conclusions from trial data is probably a controller, not a processor, and a DPA would mischaracterize that relationship.
Once the classification work is done, the DPA negotiations themselves tend to focus on a handful of areas that deserve close attention.
Due diligence should come before signing, not after. The European Data Protection Board has been clear that sponsors cannot outsource their accountability — commissioning a vendor to process trial data doesn't transfer your GDPR obligations, it just creates a contractual relationship on top of them. That means issuing data protection and security questionnaires to critical vendors, reviewing certifications like ISO 27001 or SOC 2 reports, and making sure what the vendor says they do actually matches what your DPA requires them to do.
Audit rights are a recurring negotiation sticking point. Vendors often push back with language that makes direct audits practically impossible — long notice periods, restrictions on scope, and substitution of third-party certification reports for any real oversight. Push back in return. If you can't audit a vendor processing sensitive health data from thousands of trial participants, your DPA isn't doing its job.
Breach notification timelines deserve specific numbers, not general standards. Under Article 33, you have 72 hours from awareness of a breach to notify your supervisory authority. That window is tight. If a vendor takes several days to inform you that something happened, you've missed it. Most experienced privacy teams set a contractual upstream deadline of 24 hours — sometimes less for high-severity incidents — and make sure the DPA defines "awareness" in a way that prevents vendors from running out the clock.
Sub-processor visibility is an area where many sponsors find themselves exposed when something goes wrong. Your CRO uses AWS. Your EDC vendor uses a European cloud provider that recently switched infrastructure partners. Your central lab sends sequencing work to a specialist in Singapore. Without a maintained sub-processor list and a formal change notification process, you may have transfers happening through your supply chain that you haven't assessed and can't account for. ROPA entries that reflect the full sub-processor chain — not just the primary vendor — are increasingly what regulators expect to see.
One issue that has grown significantly more important in recent years: vendor re-use of trial data for AI training. Newer commercial DPA templates increasingly include provisions allowing vendors to use customer data for "product improvement," "service enhancement," or machine learning model development. For clinical trial data, those clauses are a serious problem. Using participant health information to train a general-purpose AI model almost certainly can't be reconciled with the original research purpose under GDPR's purpose limitation principle — not without fresh consent, a new lawful basis, and clear disclosure to participants. The default in your DPA should be a hard prohibition on secondary use of trial data, with any exceptions requiring documented legal justification and participant-level transparency.
What Participants Deserve to Know: Informed Consent Forms and GDPR Transparency
The Informed Consent Form sits at one of the most important intersections in clinical research — where clinical ethics meets data protection law. It's the document that authorizes participation under Good Clinical Practice standards, and it's the primary vehicle through which sponsors meet their Article 13 transparency obligations under GDPR. Both functions have to work, and they have to work together.
Article 13 requires controllers to give individuals specific information at the point data is collected: who is the controller, how to reach the DPO, what the lawful basis for processing is, what categories of data are being collected, who the recipients are, and whether data will be transferred internationally. In a clinical trial context, all of that needs to be in the ICF — or in a dedicated privacy notice that the ICF clearly references and that participants actually receive.
The lawful basis question deserves particular care. Many sponsors default to consent for everything, but consent under GDPR is a specific legal concept that comes with strict conditions — it must be freely given, specific, informed, and unambiguous, and participants must be able to withdraw it without suffering any detriment to their trial participation. Where consent for research processing and consent for trial participation are intertwined, the GDPR's free consent requirement can be difficult to satisfy. Public interest or legitimate interests may be more appropriate bases in certain circumstances, and national law adds additional layers, particularly for health data under Article 9. The ICF should reflect the actual legal basis you're relying on, not the one that's easiest to explain.
Several ICF sections consistently create problems in regulatory and ethics reviews. Reimbursement and stipend processing often requires sharing identifiable data with third-party payment providers — a detail many ICF templates omit entirely. France's CNIL, through its reference methodology MR001, has set specific expectations about how this should be handled. Participant injury insurance information needs to identify the insurer and clarify the data flows involved. Digital tools — mobile apps, remote monitoring devices, wearables, home visit services — can collect device identifiers, location data, and household information that traditional ICF templates weren't designed to address. And where stored samples or data may support future research, the ICF needs to explain whether that involves separate consent, what purposes are envisaged, and how long data will be kept.
International transfers also need to be communicated to participants in plain language — not buried in legal annexes they'll never read. That means naming destination countries, noting whether an adequacy decision exists, and explaining in accessible terms that SCCs or equivalent safeguards are in place. The legal standard is Article 13 compliance. The practical standard is a participant who actually understands what they're agreeing to.
Building It into the Program, Not onto It
The sponsors who handle clinical trial data protection well tend to share one characteristic: they treat privacy as something that belongs at the table from the very beginning of trial design, not something that gets layered on once the protocol is finalized and the vendors are already signed.
That means bringing privacy counsel or the DPO into protocol design meetings, not just contracting reviews. It means maintaining current data flow maps that show how participant data moves between sponsors, CROs, sites, labs, and vendors — including where it crosses borders and which sub-processors are involved. And it means ensuring that the CTAs, DPAs, ICFs, Data Protection Impact Assessments, and Records of Processing Activities all tell a consistent story about roles, lawful bases, transfers, and retention periods. When those documents contradict each other — and they often do when they're drafted by different teams at different times — it's a problem that surfaces at exactly the wrong moment: during a regulatory audit or an ethics committee review.
Regulators and ethics committees are increasingly sophisticated about privacy. They're looking for evidence that data protection is embedded in a sponsor's quality system, not checked off on a compliance list. The sponsors who are positioned to move quickly and confidently in that environment are the ones who built the infrastructure before they needed it.
How PrivacyPoint Works With Life Sciences Sponsors
PrivacyPoint works with sponsors, CROs, and life sciences companies navigating GDPR, HIPAA, and CCPA in clinical research settings. Our team has hands-on experience with the specific challenges that arise in global trials — not just the regulatory framework in the abstract, but the practical decisions that come up when you're trying to get a multi-site trial off the ground without creating compliance problems that follow you for years.
We help sponsors design and negotiate CTAs and DPAs that reflect how trials actually operate. We review ICFs and participant-facing privacy notices for legal accuracy and plain-language accessibility. We map trial data flows and build ROPA documentation that stands up to scrutiny. And for sponsors who need ongoing support, we provide outsourced DPO and privacy office services that can scale with protocol amendments, vendor changes, and expansions into new countries.
The goal is always the same: privacy frameworks that match clinical timelines, so that compliance supports your research rather than slowing it down.
Reach out to us at [email protected] to talk through what your clinical trial program needs.